| UltraShape™ Granted Health Canada License to Sell Contour I System |
| Venerdì 04 Maggio 2007 00:00 |
|
UltraShape Signs Exclusive Canadian Distribution Agreement with Coherent-AMT Inc. YOQNEAM, Israel and SAN RAMON, California – May 4, 2007 – UltraShape announced today that it has been granted a medical device license to sell the UltraShape™ CONTOUR I system for non-invasive fat emulsification for the purpose of aesthetic body contouring in accordance with Health Canada’s medical device regulations. UltraShape is the first clinically proven non-invasive solution for body contouring based on focused ultrasound technology. It has been demonstrated to deliver durable and measurable circumference and fat thickness reduction in a single treatment and incremental reduction with multiple treatments. “The authorization to sell the UltraShape CONTOUR I system in Canada represents a key milestone as we establish ourselves as the leader in the non-invasive body contouring market in North America,” said Rodger Stewart, President and Chief Executive Officer of UltraShape Inc. “Additionally, with the exclusive distribution agreement with Coherent-AMT Inc., we expect rapid adoption of the UltraShape™ procedure in the Canadian marketplace, consistent with the clinical and commercial success we have experienced in 45 countries around the world.”
Coherent-AMT Inc. is Canada’s leader in aesthetic solutions representing best of class aesthetic technologies and products for the Canadian market. In signing an exclusive national distribution agreement with the company, UltraShape now has access to the largest direct sales, service and support system in Canada.
“We see significant demand for a non-invasive body contouring procedure that gives patients the option of undergoing a painless treatment for the reduction of localized fat deposits with no downtime and no required maintenance,” explained Dan Webb, Chief Executive Officer of Coherent-AMT Inc. “Combined with the high interest we have seen from leading aesthetic clinicians across the country, we are confident UltraShape will become a core procedure within aesthetic medical practices.”
UltraShape and Coherent-AMT Inc. will immediately begin conducting clinician training and educational workshops across Canada. For more information, please contact Coherent-AMT Inc. at (800) 668-5236 or visit www.aspirebecome.com/physician.
About UltraShapeUltraShape Inc., founded in 2000, is a privately held and venture backed company that develops, manufactures and markets innovative, non-invasive solutions for the aesthetic medical field. The UltraShape expert team is dedicated to the development of cutting-edge body-contouring technology in a mission to enhance patients’ self-image and sense of well-being. The UltraShape CONTOUR I, the first clinically proven non-invasive body contouring solution based on focused ultrasound technology, received the CE Mark in July 2005 and is currently distributed in 45 countries outside the United States. Over 30,000 commercial treatments have been performed to-date. ContactAmanda McNulty SheldonFischer Health +1.310.577.7870 X173 Questo indirizzo e-mail è protetto dallo spam bot. Abilita Javascript per vederlo. Abigail Marks UltraShape +972.4.909.9260 Questo indirizzo e-mail è protetto dallo spam bot. Abilita Javascript per vederlo. Dariela Roffe Porter Novelli +44.207.853.2234 Questo indirizzo e-mail è protetto dallo spam bot. Abilita Javascript per vederlo. |